Evidence map›Paper›PMID 25530343›Full record

ArticleHippocampus2015

Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss.

Rahasson R Ager, Joy L Davis, Andy Agazaryan, Francisca Benavente, Wayne W Poon, Frank M LaFerla, Mathew Blurton-Jones

Abstract read
In one paragraph

Article in Hippocampus, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rahasson R AgerInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.
Joy L DavisInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.
Andy AgazaryanInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.
Francisca BenaventeSue and Bill Gross Stem Cell Research Center, University of California, Irvine, California.
Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.
Frank M LaFerlaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.
Mathew Blurton-JonesInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California.

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI POON, WAYNE W · 2000 to 2019
$37.0M
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive DeclineK01AG029378 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BLURTON-JONES, MATHEW MARK · 2008 to 2012
$552k
NIA NIH HHS AG029378NIA NIH HHS AG16573NIA NIH HHS K01 AG029378NIA NIH HHS P50 AG016573
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disorder, affecting over 35 million people worldwide. Pathologically, AD is characterized by the progressive accumulation of β-amyloid (Aβ) plaques and neurofibrillary tangles within the brain. Together, these pathologies lead to marked neuronal and synaptic loss and corresponding impairments in cognition. Current treatments, and recent clinical trials, have failed to modify the clinical course of AD; thus, the development of novel and innovative therapies is urgently needed. Over the last decade, the potential use of stem cells to treat cognitive impairment has received growing attention. Specifically, neural stem cell transplantation as a treatment for AD offers a novel approach with tremendous therapeutic potential. We previously reported that intrahippocampal transplantation of murine neural stem cells (mNSCs) can enhance synaptogenesis and improve cognition in 3xTg-AD mice and the CaM/Tet-DT(A) model of hippocampal neuronal loss. These promising findings prompted us to examine a human neural stem cell population, HuCNS-SC, which has already been clinically tested for other neurodegenerative disorders. In this study, we provide the first evidence that transplantation of research grade HuCNS-SCs can improve cognition in two complementary models of neurodegeneration. We also demonstrate that HuCNS-SC cells can migrate and differentiate into immature neurons and glia and significantly increase synaptic and growth-associated markers in both 3xTg-AD and CaM/Tet-DTA mice. Interestingly, improvements in aged 3xTg-AD mice were not associated with altered Aβ or tau pathology. Rather, our findings suggest that human NSC transplantation improves cognition by enhancing endogenous synaptogenesis. Taken together, our data provide the first preclinical evidence that human NSC transplantation could be a safe and effective therapeutic approach for treating AD.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCell DeathCell DifferentiationCell MovementCognition DisordersDisease Models, AnimalGene Expression RegulationGlial Fibrillary Acidic ProteinHippocampusHumansMaze LearningMiceMice, TransgenicMutationAmyloid beta-Protein PrecursorGlial Fibrillary Acidic Proteintau ProteinsAlzheimer's diseaseimmune suppressionneural stem cellstherapeutictransplantation

Identifiers

PMID25530343
PMCPMC4722865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.